Viatris Inc. (VTRS) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Viatris Inc. (NASDAQ: VTRS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $19.04 (-0.86% 1D, market cap $21.86B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, VTRS ranks #184 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VTRS carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 35.2%, and ROIC of -8.1%. By comparison, ALNY (Alnylam Pharmaceuticals Inc.) holds a D+ grade (53/100 RQD, P/E 74.2x, ROIC 21.3%, cap $22.10B) and INSM (Insmed Incorporated) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $24.70B). Among the 5-stock peer group, UTHR leads on earnings multiple (19.1x) while ALNY leads on capital efficiency (21.3% ROIC).
Per VTRS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001792044), Viatris Inc. generated $14.25B in revenue (-3.0% YoY), $0 in net income, and $1.94B in free cash flow against $37.19B in total assets and $12.48B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±5.4% realized swing band)
FRED Regime × Technicals: 95% of 52W Range • RSI-14 at 62.5 (BULLISH MOMENTUM)
Capital intensity & 0% operating margin leave 13 pts on the table
Even with a 57/100 (D+) score, VTRS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 32.7% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($17.61) or 200D SMA ($15.99) invalidates the momentum regime and cuts Target Base ($18.95) toward Bear Floor ($14.78).
Viatris Inc. (VTRS) slipped -0.86% to $19.04, trading at 95% of its 52-week range ($9.92 – $19.51). Stretched risk/reward at current multiples (-8% return on capital) under elevated 10-year interest-rate pressure.
Viatris report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
For questions about this article or underlying research, email help@trefis.com.
AMGN, PFE, MRNA, NVO and VTRS are set to report this week as recent beats and key drug demand set up a pivotal Q3 earnings test for pharma giants.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -3.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VTRS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VTRS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Viatris Inc. (VTRS) ranks #184 by composite RQD confidence (57/100, grade D+) and #70 by equity capitalization ($21.86B). Within this direct 5-issuer industry benchmark cohort, UTHR leads on earnings valuation at 19.1x trailing P/E, while ALNY leads on capital efficiency and profitability with 21.3% ROIC and 81.8% gross margin. UTHR currently holds the highest overall quantitative score in the immediate peer group at 83/100 (A-) compared with VTRS at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VTRS
ACTIVE
Viatris Inc. | D+ | 57/100 | — | 35.2% | -8.1% | -0.86% | $21.86B | Benchmark Subject |
| ALNY Alnylam Pharmaceuticals Inc. | D+ | 53/100 | 74.2x | 81.8% | 21.3% | -5.17% | $22.10B | /alny-vs-vtrs → |
| INSM Insmed Incorporated | D | 44/100 | — | 79.7% | -35.0% | +0.89% | $24.70B | /insm-vs-vtrs → |
| UTHR United Therapeutics Corporation | A- | 83/100 | 19.1x | 87.9% | 20.1% | +0.87% | $25.68B | /uthr-vs-vtrs → |
| ROIV Roivant Sciences Ltd. | D- | 42/100 | — | — | -14.0% | -1.63% | $26.66B | /roiv-vs-vtrs → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viatris Inc. (VTRS) reported GAAP revenue of $14.25B (-3.0% vs. FY2024 revenue of $14.69B , and -7.4% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $2.32B, and free cash flow of $1.94B (-2.0% YoY). On the balance sheet, VTRS closed FY2025 with $37.19B in total assets against $12.48B in total debt (Altman Z-Score: 0.81, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $14.25B | $0 | $2.32B | $1.94B | $37.19B | $12.48B |
| FY2024 (FY) | 2024-12-31 | $14.69B | $0 | $2.30B | $1.98B | $41.50B | $14.04B |
| FY2023 (FY) | 2023-12-31 | $15.39B | $0 | $2.90B | $2.21B | $18.47B | $4.32B |
As of 2026-11-03, Viatris Inc. (NASDAQ: VTRS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $19.04 (-0.86% 1D, market cap $21.86B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, VTRS ranks #184 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VTRS carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 35.2%, and ROIC of -8.1%. By comparison, ALNY (Alnylam Pharmaceuticals Inc.) holds a D+ grade (53/100 RQD, P/E 74.2x, ROIC 21.3%, cap $22.10B) and INSM (Insmed Incorporated) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $24.70B). Among the 5-stock peer group, UTHR leads on earnings multiple (19.1x) while ALNY leads on capital efficiency (21.3% ROIC).
Per VTRS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001792044), Viatris Inc. generated $14.25B in revenue (-3.0% YoY), $0 in net income, and $1.94B in free cash flow against $37.19B in total assets and $12.48B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
VTRS last traded at $19.04 (-0.86% on volume of 8,793,028 shares), positioning the stock +8.12% above its 50-day simple moving average ($17.61) and +19.07% above its 200-day simple moving average ($15.99). Across its 52-week range of $9.92 to $19.51, VTRS sits at the 95.1% percentile with a 14-day RSI of 62.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.4% ($18.01 to $20.07).
Why VTRS Stock slipped -0.86% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-8% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, VTRS scores 57 out of 100, a D+ grade with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:
For a prospective investor, the composite picture is mixed: strong institutional positioning is offset by weak operating returns and a stressed balance-sheet signal. The rating's verdict is that fundamentals currently outweigh the positioning signals. The forward P/E of 33 (per Market Data) implies the market is pricing meaningful earnings recovery, which is a valuation tradeoff the RQD framework treats as a risk rather than a support.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $14250.4M | $-2663.1M | $0.0M | N/A | $1937.1M | $1322.4M | $12480.6M |
| FY 2024 | $14692.8M | $10.1M | $0.0M | N/A | $1976.9M | $734.8M | $14038.9M |
| FY 2023 | $15388.4M | $766.2M | $0.0M | N/A | $2207.5M | N/A | $4321.1M |
Per the SEC financials, revenue declined from $15388.4M (FY 2023) to $14250.4M (FY 2025), and operating income moved from $766.2M to $-2663.1M over the same span. Per the Market Data section, gross margin is 35.2%, operating margin is -18.7%, and net margin is -14.6%. Per the Roarable RQD rating, ROIC is -8.1%, the Altman Z-Score is 0.81, the Piotroski F-Score is 6/9, and Debt/Equity is 0.85. Reported net income is $0.0M in each period shown, and EPS is listed as N/A in the financial table.
Per the recent news section, the dominant catalyst is Viatris's agreement to acquire Pacira BioSciences, framed in headlines as advancing its innovative medicines strategy and non-opioid pain therapies. Multiple outlets (Yahoo Finance, Seeking Alpha, Benzinga) cover the deal, and one headline references Pacira's stock rising. A GuruFocus item cites a share price surge of 4.5% and a GF Score of 63, flagged as a catalyst. Source data does not provide deal terms, price, financing, or closing timing.
Risk watch items: the source data does not quantify deal size or how it would be funded relative to the existing $12480.6M in FY 2025 debt. The Yahoo Finance headline references "fair value," indicating valuation debate. Per the Butterfly graph, there are no supply-chain links or proprietary signals in the source data.
Real-time company headlines, analyst actions, and sector developments for Viatris Inc. (VTRS) • Click "Debate This Headline" to argue it in the Roar Pit below
Viatris report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Viatris Inc. (VTRS) market action, institutional positioning, and fundamental catalysts.
Welcome to the VTRS (Viatris Inc.) Roar Pit. Current RQD Composite is 57/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on VTRS, but look at what you are paying: current EV/EBITDA multiples with 35.2% gross margins. Unless Viatris Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on VTRS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $19.20 (52-wk range $9.92 - $19.51), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).